OpGen's Acuitas® AMR Gene Panel Shows Potential for Reducing Total Time to Targeted Therapy

Stock Information for OpGen Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About OpGen Inc.

OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
OpGen Announces Acquisition of Preferred Stock by David Lazar
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
OpGen's Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
OpGen's Subsidiary Curetis and FIND Extend R&D Collaboration Agreement
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.